LONDON, Jan. 29, 2018 (GLOBE NEWSWIRE) -- According to the new report by Meticulous Research™, the global research antibodies and reagents market will reach 13,276.5 million USD by 2022, growing at a CAGR of 6.5% during the forecast period.
“The global research antibodies and reagents market is driven by various factors such as rising proteomics & genomics research studies, increase in the funding for research activities, and growing industry-academia collaborations. In addition, growing demand for protein therapeutics & personalized medicines, rising investment & focus on the area of stem cell research, growing need for new biomarker identification, and emerging Asia-Pacific and Latin American markets provides significant opportunities in this market.” mentions Meticulous Research™.
The reagents accounted for the largest share,“mainly due to the huge demand for various reagents in many routine assays and techniques with increasing focus on understanding molecular basis of diseases, and routine use in target based assays during the basic research.”
On the basis of application, proteomics held the major share, primarily attributed to the rising need for designing more effective drugs through protein-based disease profiling, rising demand for personalized & protein therapeutics, and increasing public & private sector spending on proteomic research.
On the basis of technology, western blotting commanded the largest share mainly due to the increasing focus on biomedical research for initiating developments in diagnosis and therapy, rising funding for biomarker discovery, and growing demand for antibody & cell-based research.
Request Sample Report: https://www.meticulousresearch.com/request-sample-report/?cp_id=3642
North America commanded the largest share in the global research antibodies and reagents market in 2017, followed by Europe and Asia-Pacific. However, Asia Pacific and Latin America regions are expected to witness significant growth during the forecast period.
The key players in this market are GE Healthcare (U.S.), Merck & Co., Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Amgen Inc. (U.S.), Sanofi (France), F. Hoffmann La-Roche Ltd (Switzerland), Rockland Immunochemicals Inc. (U.S.), Johnson & Johnson (U.S.), Agilent Technologies, Inc. (U.S.), Eli Lilly and Company (U.S.), Becton Dickinson and Company (U.S.), Danaher Corporation (U.S.), PerkinElmer, Inc. (U.S.), GenScript Biotech Corporation (U.S.), Lonza (Switzerland), Bio-Techne Corporation (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Teva Pharmaceutical Industries Limited (Israel), Santa Cruz Biotechnology, Inc. (U.S.), BioLegend, Inc. (U.S.), Abcam PLC (U.K.), and Cell Signaling Technology, Inc. (U.S.).
Browse in-depth report on: https://www.meticulousresearch.com/product/research-antibodies-reagents-market-2023/
Contact Info:
Viren Shrivastava
Email: viren@meticulousresearch.com
Direct Lines: +1-646-781-8004 (North America)
+44-203-868-8738 (Europe)